Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Stopped Enrollment halted during phase 2 to reformulate the investigational product
Conditions
Interventions
- DRUG: Oprozomib
- DRUG: Dexamethasone
Sponsor
Amgen